A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.
Also called NCT07107945
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 135 participants
- Sponsor
- Registry
-
NCT07107945 -
2024-512577-27-00 -
U1111-1312-1389
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Singapore, South Korea, Spain, Sweden, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07107945. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-09 (actual); primary completion 2027-04-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct07107945- Content hash
31fe576e20d2f88906a01b9233881c37f615a86ec56b5541e19d4abbe2173765